AmplifiDx develops the DX 100™ platform, a molecular point-of-care diagnostic device that utilizes advanced multiplex technology to deliver rapid and accurate test results for family and women's health. This device addresses the need for affordable and efficient diagnostics, enabling healthcare professionals and patients to obtain reliable results in under one minute with minimal hands-on time.

AngioInsight is a fully automated platform that utilizes advanced algorithms for the interpretation of coronary angiogram videos. This technology enhances diagnostic accuracy and efficiency, addressing the challenges of manual image analysis in cardiovascular care.

This company develops small molecule antiviral drugs targeting infections caused by HPV, herpes viruses, HIV, and animal retroviruses. Their medicinal chemistry platform aims to create direct-acting antivirals, helping patients recover from viral diseases.

AOA Dx is developing GlycoLocate™, a multi-omics platform that utilizes tumor marker gangliosides for early-stage cancer detection, specifically through the AKRIVIS GD™ liquid biopsy test for ovarian cancer. This technology offers high sensitivity and specificity, addressing the critical need for effective early diagnosis in women's health.

Avation Medical has developed the Vivally® System, a wearable physiologic closed-loop neuromodulation device that utilizes transcutaneous tibial nerve stimulation to treat overactive bladder (OAB) symptoms at home. This FDA-cleared system allows patients to manage urinary urgency and urge urinary incontinence with just 30 minutes of use, one to three times a week, while tracking their progress through a mobile application.

Axena Health develops the Leva® Pelvic Health System, a non-drug, non-surgical device that utilizes pelvic floor muscle training to improve bladder leakage symptoms in women. The technology provides measurable benefits by enabling users to achieve significant improvements in urinary incontinence within four weeks.

Clarified Precision Medicine operates a scalable asynchronous Molecular Tumor Board that interprets genomic tumor profiling using NCCN guidelines, enabling oncologists to make informed treatment decisions based on individual tumor profiles. The platform enhances the utilization of targeted therapies, resulting in a 50% increase in appropriate clinical recommendations and reducing the time spent on data interpretation by up to one hour per patient.

Curio provides AI-driven care navigation and personalized mental health support, enabling users to access tailored resources and expert guidance for managing chronic conditions like PTSD, cancer, and long COVID. The platform empowers patients with 24/7 access to financial resources, emotional support, and treatment options, enhancing their ability to take control of their health journey.

Dahlia Biosciences offers RNA Flow Assays that enable ultra-throughput single-cell gene expression analysis using proprietary in situ detection chemistry. This technology allows researchers to rapidly detect multiple RNA targets with high sensitivity and specificity, generating data in less than a day while integrating seamlessly into existing flow cytometry workflows.

DIA provides a decentralized oracle platform that utilizes a rollup architecture to deliver real-time, verifiable data across over 50 blockchain networks, supporting more than 20,000 assets. This technology addresses the need for reliable and transparent data feeds in decentralized applications, enabling developers to integrate accurate price information without relying on third-party sources.

Elucent Medical develops a breast cancer detection system that utilizes SmartClip technology and the EnVisio Navigation system to accurately locate tumor margins in real-time during surgical excision. This approach eliminates the need for metal clips, enhances surgical precision, and minimizes tissue removal, ultimately improving patient outcomes and satisfaction.

The startup develops small molecule inhibitors that target the endothelia receptor to reverse drug resistance in cancer patients undergoing immunotherapy. This approach aims to reduce tumor growth and extend survival in various cancers that are resistant to current immunotherapy treatments.

The startup provides genomic medicine delivery by connecting individuals and healthcare providers with genetic experts for personalized genetic assessments and clinical action plans. This approach enables patients to make informed treatment decisions while facilitating faster disease diagnosis for medical practitioners at reduced costs.

Heal is a nonprofit ecommerce platform that utilizes experience-based peer support to help individuals with mental illness reconnect with their passions through creative expression. By empowering emerging artists to showcase their work, Heal reinvests 100% of its profits into community-building initiatives that foster meaningful connections.

Madorra develops a nonhormonal, noninvasive medical device to treat moderate to severe vulvovaginal atrophy, a condition that causes vaginal dryness in post-menopausal individuals and breast cancer survivors. By providing an alternative to pharmaceutical treatments, Madorra empowers users to manage their vaginal health effectively.

Mae connects expectant mothers with community-based doulas and dedicated care coordinators to provide personalized support throughout pregnancy and postpartum. The platform integrates with health insurance plans to facilitate access to evidence-based maternal health resources and education. This integrated approach aims to improve maternal health outcomes, including reductions in preterm birth and C-section rates.

May Health is developing Ovarian Rebalancing™, a one-time outpatient treatment that utilizes targeted ovarian ablation to lower androgen production and restore ovulation in individuals with Polycystic Ovary Syndrome (PCOS) related infertility. Currently in clinical trials, this investigational treatment aims to provide a hormone-free solution for those struggling with ovulatory dysfunction due to PCOS.

Mercy BioAnalytics utilizes its proprietary Mercy Halo™ platform, which employs low-cost qPCR technology to detect cancer-associated biomarkers on extracellular vesicles in blood samples. This approach addresses the challenge of late cancer diagnoses by providing highly sensitive and specific tests for early-stage cancer detection, improving treatment options and patient outcomes.

Midi Health provides virtual consultations with clinicians specialized in midlife women's health, focusing on conditions such as menopause, depression, and gynecological issues. The platform offers personalized care plans and prescription management, ensuring accessible treatment options covered by insurance across all 50 states.

Novocuff develops a medical device that monitors uterine contractions to identify women at risk of preterm birth. By providing real-time data, the device aims to improve pregnancy outcomes and reduce the incidence of premature deliveries.

The startup operates a zero-knowledge oracle network for Ethereum, utilizing zero-knowledge proofs to facilitate secure off-chain computation for tasks such as automation and machine learning inference. This technology enhances the functionality and reliability of smart contracts, enabling developers to create more sophisticated decentralized applications without compromising on trust or security.